Clinical trials
Marginal Zone B Cell Lymphoma clinical trials
Below are recruiting marginal zone b cell lymphoma clinical trials, each written for real people, not researchers. We’re tracking 126 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05643742RecruitingPhase 1/Phase 2
Study of CTX112 for B-cell cancers that came back or did not respond
This Phase 1/2 study tests how safe and effective CTX112 is for adults whose B-cell cancer has returned or is not responding to treatment. It aims to see whether CTX112 can control the cancer while monitoring side effects closely.
Westwood, KansasAges 18 years+ - NCT05773040RecruitingPhase 1
CAR T-cell therapy made from your own immune cells
This Phase 1 trial tests an “autologous” CAR T-cell treatment (made from your own T cells) that targets a cancer marker called CD79b in certain relapsed or hard-to-treat B-cell lymphomas. It’s designed to find a safe dose and see whether the treatment can shrink tumors and help control the lymphoma after prior therapies.
Houston, TexasAges 18 years+ - NCT05794958RecruitingPhase 1
Safety of second CAR-T re-infusion for hard-to-treat lymphoma
This Phase 1 study tests whether a second re-infusion of axicabtagene ciloleucel (CAR-T) is safe in people with aggressive B-cell non-Hodgkin lymphoma that came back or did not respond after standard second-line CAR-T. It may help some patients by trying to improve disease control while carefully monitoring side effects.
Palo Alto, CaliforniaAges 18 years+ - NCT05805605RecruitingPhase 2
Low-intensity stem cell transplant with donor cells and blood-protection
This Phase 2 study tests a low-intensity bone marrow/stem cell transplant using a matched donor plus two medicines to help prevent the donor cells from attacking you. It aims to treat certain blood cancers—especially when standard treatment has not fully worked or when you are in remission but at higher risk.
Minneapolis, MinnesotaAges Up to 75 years - NCT05846750RecruitingPhase 2
Obinutuzumab plus lenalidomide for relapsed marginal zone lymphoma
This trial studies whether obinutuzumab combined with lenalidomide can control marginal zone lymphoma that has come back or not responded to prior treatment. If you qualify, you may receive these medicines together to help shrink tumors and improve symptoms.
Tianjin, TianAges 18 years+ - NCT05852717RecruitingPhase 2
Epcoritamab plus GDP chemotherapy for relapsed large B-cell lymphoma
This Phase 2 study tests epcoritamab combined with GDP chemotherapy to treat adults whose large B-cell lymphoma has come back or did not respond to prior treatment. It aims to improve how safely and effectively the disease can be controlled after standard chemotherapy.
Indianapolis, IndianaAges 18 years+ - NCT05929612RecruitingPhase 2
Low-dose targeted radiation alone for marginal zone lymphoma
This Phase 2 study tests whether very low-dose radiation (adjusted based on how you respond) can treat marginal zone lymphoma without adding other medicines at first. It may help some people by reducing radiation exposure while still controlling the cancer.
Houston, TexasAges 18 years+ - NCT06006117RecruitingPhase 3
Testing a new drug combination for relapsed marginal zone lymphoma
This trial compares a combination of mosunetuzumab and lenalidomide against standard treatments for people with marginal zone lymphoma that has come back or stopped responding to previous therapy. It aims to find out if the new combination works better than current options.
AnderlechtAges 18 years+ - NCT06026319RecruitingPhase 1
CAR T cells targeting CD79b and CD19 for non-Hodgkin lymphoma
This trial tests a new type of CAR T-cell therapy that targets two proteins (CD79b and CD19) on lymphoma cells. It's for people with certain types of non-Hodgkin lymphoma that have come back or not responded to previous treatments.
Boston, MassachusettsAges 18 years+ - NCT06043011Recruiting
Registry for non-Hodgkin lymphoma patients on systemic therapy
This registry tracks people with non-Hodgkin lymphoma who are starting a new line of systemic therapy. It collects information to better understand how treatments work in real life, and optionally asks you to fill out surveys about your symptoms and quality of life.
Freiburg im BreisgauAges 18 years+ - NCT06082102RecruitingPhase 3
Comparing orelabrutinib and lenalidomide with rituximab for MZL
This study tests two different drug combinations for people with marginal zone lymphoma that has come back or stopped responding to previous treatment. One group gets orelabrutinib plus rituximab, and the other gets lenalidomide plus rituximab, to see which works better and has fewer side effects.
Bengbu, AuhuiAges 18 years+ - NCT06149286RecruitingPhase 3
Testing a new drug combo for follicular and marginal zone lymphoma
This trial is testing if a new drug called odronextamab combined with lenalidomide works better than the standard treatment (rituximab with lenalidomide) for adults with follicular lymphoma or marginal zone lymphoma that has come back or stopped responding to previous therapy.
Los Angeles, CaliforniaAges 18 years+ - NCT06151730Recruiting
Managing blood pressure and heart risks during BTKi treatment
This study looks at how well blood pressure is managed and whether heart problems can be prevented in people with certain blood cancers who are taking a type of targeted therapy called a BTKi. It aims to help you stay healthier during treatment.
Rochester, MinnesotaAges Any age - NCT06180174RecruitingPhase 1
CD19-targeted CAR-T cells for relapsed B-cell lymphoma
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called CD19 on your lymphoma cells. It's for people whose B-cell lymphoma has returned or not responded to standard treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06189391RecruitingPhase 1
Testing CN201 for people with relapsed or refractory B-cell lymphoma
This study tests a new drug called CN201 (also known as MK-1045) for people with certain types of B-cell lymphoma that have come back or not responded to previous treatments. The goal is to see if the drug can help shrink or control the cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT06191887RecruitingPhase 1
BAFFR-targeting CAR-T cells for relapsed B-cell blood cancers
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called BAFFR on B-cell blood cancers. The goal is to see if it can shrink tumors when given after a short chemotherapy course to prepare the body.
Jacksonville, FloridaAges 18 years+ - NCT06323525RecruitingPhase 1/Phase 2
Modified CAR-T cell therapy for relapsed/refractory B-cell lymphoma
This trial tests a new type of CAR-T cell therapy for people with certain B-cell lymphomas that have come back or not responded to treatment. The CAR-T cells are made from a donor and are genetically edited to possibly work better and last longer.
Beijing, Beijing MunicipalityAges 18–70 - NCT07101328RecruitingPhase 1
Study of LY4152199 for Lymphoma That Returned or Didn't Respond
This study tests a new medicine called LY4152199 for people with certain types of lymphoma (follicular or diffuse large B-cell) that came back or didn't respond to previous treatment. The goal is to see if the drug is safe and how well it works.
Duarte, CaliforniaAges 18 years+ - NCT06340737RecruitingPhase 1
CD22-targeting CAR T cells for relapsed B cell lymphoma
This trial tests whether giving modified immune cells (CAR T cells) that target CD22 on cancer cells can help people with certain B-cell lymphomas that have come back or not responded to at least two prior treatments. The goal is to see if this approach can shrink tumors or control the disease.
Palo Alto, CaliforniaAges 18 years+ - NCT06350318RecruitingPhase 2
Rituximab and Zanubrutinib for slow-growing B-cell lymphomas
This trial tests a combination of two targeted drugs (rituximab and zanubrutinib) for people with slow-growing B-cell lymphomas like marginal zone or follicular lymphoma. It may be a good option if you haven't had treatment for your lymphoma before and your disease needs therapy to manage symptoms.
Tampa, FloridaAges 18 years+ - NCT06415708RecruitingPhase 2
Obinutuzumab with bendamustine for B-cell lymphoma
This trial tests a combination of two drugs—obinutuzumab and bendamustine—for people with certain B-cell lymphomas that haven't been treated before. The goal is to see how well this combination works and how safe it is.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06442475RecruitingPhase 2
Low-dose mosunetuzumab for untreated indolent B-cell lymphoma
This trial tests a low dose of the drug mosunetuzumab for people with slow-growing B-cell lymphomas (follicular lymphoma or marginal zone lymphoma) who have not had any previous treatment. It aims to see if this drug can help control the disease with fewer side effects.
Seattle, WashingtonAges 18 years+ - NCT06454968RecruitingPhase 2
Combination therapy for first-line marginal zone lymphoma
This study tests a combination of three drugs—orelabrutinib, obinutuzumab, and lenalidomide—as a first treatment for marginal zone lymphoma. The goal is to see if this mix of targeted therapies works well and safely.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06478472Recruiting
Orelabrutinib plus rituximab for marginal zone lymphoma
This trial tests a combination of two targeted therapies—oralebrutinib (a pill that blocks a protein in cancer cells) and rituximab (an antibody infusion)—for people with marginal zone lymphoma that has returned or cannot be treated with local therapies. The goal is to see if this combo works well and is safe.
Xiamen, FujianAges 18 years+
Hear when a new Marginal Zone B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for marginal zone b cell lymphoma?
- Yes. Clin2 currently lists 126 recruiting marginal zone b cell lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a marginal zone b cell lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a marginal zone b cell lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.